secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001628280-23-008677
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma FY2022 net loss $93.9M; WHIM trial success, NDA submission planned for H2 2023
--------------------------------------------------------------------------------

- Cash $123M as of Dec 31, 2022; funds operations into Q2 2024.
- Phase 3 4WHIM trial met primary and key secondary endpoints; NDA submission expected early 2H 2023.
- Phase 2 chronic neutropenia trial enrolling; data and regulatory path clarity expected 2Q/3Q 2023.
- Gross proceeds ~$120M from two 2022 financings; amended Hercules loan lowered cash covenant to $20M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023008677/0001628280-23-008677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023008677/xfor-20230321.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-008677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer